FDA Grants Approval for Genetically Engineered Salmon

Share this content:
FDA Grants Approval for Genetically Engineered Salmon
FDA Grants Approval for Genetically Engineered Salmon

FRIDAY, Nov. 20, 2015 (HealthDay News) -- The U.S. Food and Drug Administration approved on Thursday a Massachusetts company's request to produce genetically modified salmon.

"The FDA has thoroughly analyzed and evaluated the data and information submitted by AquaBounty Technologies regarding AquAdvantage Salmon and determined that they have met the regulatory requirements for approval, including that food from the fish is safe to eat," Bernadette Dunham, D.V.M., Ph.D., director of the FDA's Center for Veterinary Medicine, said at a media briefing.

After five years of study, the FDA didn't find any nutritional difference between the genetically modified salmon and conventional salmon, Durham said. The FDA isn't aware of any information that foods from genetically engineered sources differ from their non-genetically engineered counterparts or are less safe, she added.

Under FDA approval, AquaBounty Technologies cannot raise the salmon in the United States; it can only be raised on fish farms in Canada and Panama. Also, no other company is authorized to raise this type of fish for sale in the United States, the agency said. The FDA said it's convinced that measures will be put in place to prevent the genetically altered salmon from escaping from the farms and into the wild, so they wouldn't affect the environment. The FDA and the governments of Canada and Panama will inspect the facilities.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths